Literature DB >> 17510322

The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo.

Kristy Boyle1, Paul Egan, Steven Rakar, Tracy A Willson, Ian P Wicks, Donald Metcalf, Douglas J Hilton, Nicos A Nicola, Warren S Alexander, Andrew W Roberts, Lorraine Robb.   

Abstract

Suppressor of cytokine signaling 3 (SOCS3) is a negative regulator of granulocyte-colony stimulating factor (G-CSF) signaling in vivo. SOCS proteins regulate cytokine signaling by binding, via their SH2 domains, to activated cytokine receptors or their associated Janus kinases. In addition, they bind to the elongin B/C ubiquitin ligase complex via the SOCS box. To ascertain the contribution of the SOCS box of SOCS3 to in vivo regulation of G-CSF signaling, we generated mice expressing a truncated SOCS3 protein lacking the C-terminal SOCS box (SOCS3(Delta SB/Delta SB)). SOCS3(Delta SB/Delta SB) mice were viable, had normal steady-state hematopoiesis, and did not develop inflammatory disease. Despite the mild phenotype, STAT3 activation in response to G-CSF signaling was prolonged in SOCS3(Delta SB/Delta SB) bone marrow. SOCS3(Delta SB/Delta SB) bone marrow contained increased numbers of colony-forming cells responsive to G-CSF and IL-6. Treatment of the mice with pharmacologic doses of G-CSF, which mimics emergency granulopoiesis and therapeutic use of G-CSF, revealed that SOCS3(Delta SB/Delta SB) mice were hyperresponsive to G-CSF. Compared with wild-type mice, SOCS3(Delta SB/Delta SB) mice developed a more florid arthritis when tested using an acute disease model. Overall, the results establish a role for the SOCS box of SOCS3 in the in vivo regulation of G-CSF signaling and the response to inflammatory stimuli.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17510322      PMCID: PMC1975836          DOI: 10.1182/blood-2007-03-079178

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  57 in total

1.  VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases.

Authors:  Takumi Kamura; Katsumi Maenaka; Shuhei Kotoshiba; Masaki Matsumoto; Daisuke Kohda; Ronald C Conaway; Joan Weliky Conaway; Keiichi I Nakayama
Journal:  Genes Dev       Date:  2004-12-15       Impact factor: 11.361

2.  The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability.

Authors:  Jeffrey J Babon; Edward J McManus; Shenggen Yao; David P DeSouza; Lisa A Mielke; Naomi S Sprigg; Tracy A Willson; Douglas J Hilton; Nicos A Nicola; Manuel Baca; Sandra E Nicholson; Raymond S Norton
Journal:  Mol Cell       Date:  2006-04-21       Impact factor: 17.970

3.  Acute CD4+ T lymphocyte-dependent interleukin-1-driven arthritis selectively requires interleukin-2 and interleukin-4, joint macrophages, granulocyte-macrophage colony-stimulating factor, interleukin-6, and leukemia inhibitory factor.

Authors:  Kate E Lawlor; Peter K K Wong; Ian K Campbell; Nico van Rooijen; Ian P Wicks
Journal:  Arthritis Rheum       Date:  2005-12

4.  Gene delivery of SOCS3 protects mice from lethal endotoxic shock.

Authors:  Min Fang; Hong Dai; Guang Yu; Feili Gong
Journal:  Cell Mol Immunol       Date:  2005-10       Impact factor: 11.530

5.  Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis.

Authors:  Daewoong Jo; Danya Liu; Shan Yao; Robert D Collins; Jacek Hawiger
Journal:  Nat Med       Date:  2005-07-10       Impact factor: 53.440

6.  Genetic reduction of embryonic leukemia-inhibitory factor production rescues placentation in SOCS3-null embryos but does not prevent inflammatory disease.

Authors:  Lorraine Robb; Kristy Boyle; Steven Rakar; Lynne Hartley; Janelle Lochland; Andrew W Roberts; Warren S Alexander; Donald Metcalf
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-28       Impact factor: 11.205

7.  SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation.

Authors:  Gillian M Tannahill; Joanne Elliott; Anna C Barry; Linda Hibbert; Nicolas A Cacalano; James A Johnston
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

8.  The N-terminal truncated isoform of SOCS3 translated from an alternative initiation AUG codon under stress conditions is stable due to the lack of a major ubiquitination site, Lys-6.

Authors:  Atsuo Sasaki; Kyoko Inagaki-Ohara; Takafumi Yoshida; Atsushi Yamanaka; Mika Sasaki; Hideo Yasukawa; Antonis E Koromilas; Akihiko Yoshimura
Journal:  J Biol Chem       Date:  2002-11-28       Impact factor: 5.157

9.  Absence of suppressor of cytokine signalling 3 reduces self-renewal and promotes differentiation in murine embryonic stem cells.

Authors:  Ariel Forrai; Kristy Boyle; Adam H Hart; Lynne Hartley; Steven Rakar; Tracy A Willson; Ken M Simpson; Andrew W Roberts; Warren S Alexander; Anne K Voss; Lorraine Robb
Journal:  Stem Cells       Date:  2005-08-25       Impact factor: 6.277

10.  SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis.

Authors:  Peter K K Wong; Paul J Egan; Ben A Croker; Kristy O'Donnell; Natalie A Sims; Sarah Drake; Hiu Kiu; Edward J McManus; Warren S Alexander; Andrew W Roberts; Ian P Wicks
Journal:  J Clin Invest       Date:  2006-05-18       Impact factor: 14.808

View more
  30 in total

Review 1.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

2.  Discovering early molecular determinants of leukemogenesis.

Authors:  Grover C Bagby
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

3.  Deletion of the SOCS box of suppressor of cytokine signaling 3 (SOCS3) in embryonic stem cells reveals SOCS box-dependent regulation of JAK but not STAT phosphorylation.

Authors:  Kristy Boyle; Jian-Guo Zhang; Sandra E Nicholson; Evelyn Trounson; Jeffery J Babon; Edward J McManus; Nicos A Nicola; Lorraine Robb
Journal:  Cell Signal       Date:  2008-11-12       Impact factor: 4.315

4.  SPSB1, a Novel Negative Regulator of the Transforming Growth Factor-β Signaling Pathway Targeting the Type II Receptor.

Authors:  Sheng Liu; Thao Nheu; Rodney Luwor; Sandra E Nicholson; Hong-Jian Zhu
Journal:  J Biol Chem       Date:  2015-06-01       Impact factor: 5.157

Review 5.  Emergency granulopoiesis.

Authors:  Markus G Manz; Steffen Boettcher
Journal:  Nat Rev Immunol       Date:  2014-04-22       Impact factor: 53.106

Review 6.  Inhibition of IL-6 family cytokines by SOCS3.

Authors:  Jeffrey J Babon; Leila N Varghese; Nicos A Nicola
Journal:  Semin Immunol       Date:  2014-01-10       Impact factor: 11.130

7.  Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity.

Authors:  Jeffrey J Babon; Nadia J Kershaw; James M Murphy; Leila N Varghese; Artem Laktyushin; Samuel N Young; Isabelle S Lucet; Raymond S Norton; Nicos A Nicola
Journal:  Immunity       Date:  2012-02-24       Impact factor: 31.745

8.  Reconstruction of an active SOCS3-based E3 ubiquitin ligase complex in vitro: identification of the active components and JAK2 and gp130 as substrates.

Authors:  Nadia J Kershaw; Artem Laktyushin; Nicos A Nicola; Jeffrey J Babon
Journal:  Growth Factors       Date:  2014-01-20       Impact factor: 2.511

9.  The SOCS box encodes a hierarchy of affinities for Cullin5: implications for ubiquitin ligase formation and cytokine signalling suppression.

Authors:  Jeffrey J Babon; Jennifer K Sabo; Jian-Guo Zhang; Nicos A Nicola; Raymond S Norton
Journal:  J Mol Biol       Date:  2009-03-20       Impact factor: 5.469

Review 10.  SOCS regulation of the JAK/STAT signalling pathway.

Authors:  Ben A Croker; Hiu Kiu; Sandra E Nicholson
Journal:  Semin Cell Dev Biol       Date:  2008-07-30       Impact factor: 7.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.